Serial Magnetic Resonance Imaging to Identify Early Stages of Anthracycline-Induced Cardiotoxicity

2Citations
Citations of this article
22Readers
Mendeley users who have this article in their library.

Abstract

Background: Anthracycline-induced cardiotoxicity is a major clinical problem, and early cardiotoxicity markers are needed. Objectives: The purpose of this study was to identify early doxorubicin-induced cardiotoxicity by serial multiparametric cardiac magnetic resonance (CMR) and its pathological correlates in a large animal model. Methods: Twenty pigs were included. Of these, 5 received 5 biweekly intracoronary doxorubicin doses (0.45 mg/kg/injection) and were followed until sacrifice at 16 weeks. Another 5 pigs received 3 biweekly doxorubicin doses and were followed to 16 weeks. A third group was sacrificed after the third dose. All groups underwent weekly CMR examinations including anatomical and T 2 and T 1 mapping (including extracellular volume [ECV] quantification). A control group was sacrificed after the initial CMR. Results: The earliest doxorubicin-cardiotoxicity CMR parameter was T 2 relaxation-time prolongation at week 6 (2 weeks after the third dose). T 1 mapping, ECV, and left ventricular (LV) motion were unaffected. At this early time point, isolated T 2 prolongation correlated with intracardiomyocyte edema secondary to vacuolization without extracellular space expansion. Subsequent development of T 1 mapping and ECV abnormalities coincided with LV motion defects: LV ejection fraction declined from week 10 (2 weeks after the fifth and final doxorubicin dose). Stopping doxorubicin therapy upon detection of T 2 prolongation halted progression to LV motion deterioration and resolved intracardiomyocyte vacuolization, demonstrating that early T 2 prolongation occurs at a reversible disease stage. Conclusions: T 2 mapping during treatment identifies intracardiomyocyte edema generation as the earliest marker of anthracycline-induced cardiotoxicity, in the absence of T 1 mapping, ECV, or LV motion defects. The occurrence of these changes at a reversible disease stage shows the clinical potential of this CMR marker for tailored anthracycline therapy.

Cite

CITATION STYLE

APA

Galán-Arriola, C., Lobo, M., Vílchez-Tschischke, J. P., López, G. J., de Molina-Iracheta, A., Pérez-Martínez, C., … Ibanez, B. (2019). Serial Magnetic Resonance Imaging to Identify Early Stages of Anthracycline-Induced Cardiotoxicity. Journal of the American College of Cardiology, 73(7), 779–791. https://doi.org/10.1016/j.jacc.2018.11.046

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free